Summary
Generic Patent Challenges on Blockbuster Drugs and How Drug Companies Successfully Defended Against Them
Join us for a roundtable discussion on the patent strategies that small molecule therapeutics companies with recently-approved or late-stage clinical trial drugs have used to succeed (or fail) in protecting product sales. Our speakers – leaders in life sciences patent and market economics, generic and brand Hatch-Waxman litigation, and late-stage patent strategy – will highlight best practices surrounding market exclusivity and patent protection against generic (ANDA) filers. The webinar will dig deeper into a number of examples where patent protection provided significant market exclusivity beyond the regulatory exclusivities, and will identify the key take-aways for companies that are nearing FDA approval and are poised to launch their commercial products.
Goodwin Partners Theresa Kavanaugh will be joined by Sally Woodhouse, Senior Vice President Cornerstone Research.
1.0 Hour of CA and NY CLE Credit Available.
Speakers
- /en/people/k/kavanaugh-theresa
Theresa C. Kavanaugh
Partner